Bioline Rx Stock Price To Book
| BLRX Stock | ILS 8.10 0.10 1.25% |
BioLine RX fundamentals help investors to digest information that contributes to BioLine RX's financial success or failures. It also enables traders to predict the movement of BioLine Stock. The fundamental analysis module provides a way to measure BioLine RX's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLine RX stock.
BioLine |
BioLine RX Company Price To Book Analysis
BioLine RX's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current BioLine RX Price To Book | 0.77 X |
Most of BioLine RX's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLine RX is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, BioLine RX has a Price To Book of 0.7684 times. This is 97.01% lower than that of the Biotechnology sector and 87.28% lower than that of the Health Care industry. The price to book for all Israel stocks is 91.92% higher than that of the company.
BioLine Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLine RX's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics of similar companies.BioLine RX is currently under evaluation in price to book category among its peers.
BioLine Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Current Ratio | 5.12 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 38 | |||
| Beta | 1.27 | |||
| Market Capitalization | 135.72 M | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Working Capital | 43 M | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 4.4 | |||
| Net Asset | 81.39 M |
About BioLine RX Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.